January 23, 2017 11:28 am | Leave your thoughts
We are very pleased to announce the appointment of Mark Johnson as the new Director of Clinical Trial Services at Client Pharma CTS. Mark’s considerable knowledge of the global pharmaceutical supply chain and experience within the industry furthers Client Pharma CTS’s ability to support manufacturers, sponsors, biotechs, CROs and patients alike. He will be playing
January 17, 2017 1:58 pm | Leave your thoughts
Researchers from the University of Massachusetts and Newcastle University have argued that clinical trial design for biosimilars needs to be standardized after highlighting differences in the safety evaluations and findings between clinical trials for these drugs. The researchers identified that different designs have been employed in some phase III clinical trials when comparing biosimilar TNF
January 6, 2017 12:35 pm | Leave your thoughts
The cost of drugs to treat cancer has been increasing significantly around the world. This is partly due to the introduction of new therapies to treat the condition; however, with so much research, development and innovation being made there is uncertainty around how health care systems will be able to afford these advancements. Following the
October 10, 2016 4:03 pm | Leave your thoughts
In recent years, drug prices have come under increased global scrutiny. As globally people live longer and cures for previously incurable conditions are found, the need for affordable and timely access to medicine has never been more essential. Although the price of medicine is not strictly within the remit of regulatory bodies, drug regulators can
September 29, 2016 1:38 pm | Leave your thoughts
Client-Pharma will be visiting CPHI Barcelona from 4-6th October. The exhibition, together with co-located events ICSE, InnoPack, P-MEC and FDF, will be a great opportunity for Client-Pharma to meet with existing and potential clients and stay up to date on all the latest industry trends and market news. CPHI Barcelona is the world’s leading pharmaceutical platform. Taking
July 21, 2016 12:15 pm | Leave your thoughts
Japan has been named an emerging market for biosimilars as the uptake for some products is now on a par with generics. Over the past few years, biologics have gained significant traction in the pharmaceutical industry. By 2020 biosimilars are predicted to comprise 27% of the pharmaceutical market, generating a predicted revenue of $290 billion.
March 15, 2016 10:33 am | Leave your thoughts
Based on IMS health data, speciality pharmaceuticals are said to make up a quarter of prescription costs within the pharmaceutical market. This is purported to be the fastest growing costs within healthcare today. Used to treat specific cancers and rare diseases, they are termed ‘speciality’ due to their unusual or difficult process of delivery. IMS
February 8, 2016 12:44 pm | Leave your thoughts
Last month Client Pharma attended Arab Health 2016. Taking place in the International Convention and Exhibition Centre in Dubai, the healthcare exhibition is both the region’s largest and one of the biggest in the world. In its 41st edition, Arab Health is a unique platform for companies to unveil their latest innovations within the healthcare
December 11, 2015 11:00 am | Leave your thoughts
The price of drugs and innovation into cures are inextricably linked. The subject of drug affordability and attainability is undoubtedly fraught with emotion. The high price that drugs are often sold for means that they are only available to those who have the capital to afford them. In countries where healthcare systems are government led
November 3, 2015 4:26 pm | Leave your thoughts
Taking counterfeit medicines, either knowingly or unknowingly, can trigger dangerous side effects or cause serious health risks. The majority of counterfeit medicines are manufactured in developing countries such as Asia, Africa and Latin America as laws and government regulations are not as stringent in these countries. In some environments where counterfeit drugs are manufactured, the
